Cargando…

Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier

Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Myc...

Descripción completa

Detalles Bibliográficos
Autores principales: Düzgüneş, Nejat, Sessevmez, Melike, Yildirim, Metin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824886/
https://www.ncbi.nlm.nih.gov/pubmed/33466546
http://dx.doi.org/10.3390/ph14010034
_version_ 1783640186137083904
author Düzgüneş, Nejat
Sessevmez, Melike
Yildirim, Metin
author_facet Düzgüneş, Nejat
Sessevmez, Melike
Yildirim, Metin
author_sort Düzgüneş, Nejat
collection PubMed
description Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii.
format Online
Article
Text
id pubmed-7824886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78248862021-01-24 Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier Düzgüneş, Nejat Sessevmez, Melike Yildirim, Metin Pharmaceuticals (Basel) Review Antibiotic-resistant infections present a serious health concern worldwide. It is estimated that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections. Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii. MDPI 2021-01-05 /pmc/articles/PMC7824886/ /pubmed/33466546 http://dx.doi.org/10.3390/ph14010034 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Düzgüneş, Nejat
Sessevmez, Melike
Yildirim, Metin
Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title_full Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title_fullStr Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title_full_unstemmed Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title_short Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier
title_sort bacteriophage therapy of bacterial infections: the rediscovered frontier
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824886/
https://www.ncbi.nlm.nih.gov/pubmed/33466546
http://dx.doi.org/10.3390/ph14010034
work_keys_str_mv AT duzgunesnejat bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier
AT sessevmezmelike bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier
AT yildirimmetin bacteriophagetherapyofbacterialinfectionstherediscoveredfrontier